We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

MedXY Editorial Team•Dec 10, 2025•Hematology-Oncology
Large B-Cell Lymphomamosunetuzumab

Highlights

– In SUNMO (phase III, randomized 2:1), mosunetuzumab plus polatuzumab vedotin (Mosun‑Pola) produced a higher overall response rate (70% vs 40%) and longer median progression‑free survival (11.5 vs 3.8 months; HR 0.41) compared with R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma (LBCL).

– Complete response rates were substantially higher with Mosun‑Pola (51% vs 24%).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 StudyLisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.Sep 18, 2026Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based AssayThis study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay foAug 25, 2026Response Kinetics Following CAR T-Cell Therapy for Large B-Cell Lymphoma: Insights from the LYSA DESCAR-T RegistryThis review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from partiAug 24, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell LymphomaThis study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating aAug 17, 2026
Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with ObinutuzumabA novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable saAug 17, 2026
Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell LymphomaA retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.May 11, 2026